US EditionPublished • loading... • Updated
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore
Summary by Globe Newswire
14 Articles
14 Articles
Globe Newswire+12 Reposted by 12 other sources
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore
InnoCare's HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with R/R MZL....
(SeaPRwire) – BEIJING, September 7, 2025 – InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focused on cancer and autoimmune diseases, today announced that HIBRUKA (orelabrutinib) has been approved by the Singapore Health Sciences Authority (HSA) for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (R/R MZL). Dr. Jisong Cui, Co-founder, Chairman and CEO of InnoCare, said: “We are p…
Coverage Details
Total News Sources14
Leaning Left9Leaning Right2Center1Last UpdatedBias Distribution75% Left
Bias Distribution
- 75% of the sources lean Left
75% Left
L 75%
R 17%
Factuality
To view factuality data please Upgrade to Premium
